Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 12;12:10931–10941. doi: 10.2147/OTT.S233234

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Liu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Knockdown of PRKD2-inhibited drug resistance by inducing apoptosis. (A, B) PRKD2 expression was knocked down by siRNAs in KASUMI and U937 cells. The mRNA level of PRKD2 was detected by qRT-PCR. The protein level of PRKD2 was detected by Western blot. (C) KASUMI and U937 cells were treated with ADM for 48 hrs, and cell viability was detected by CCK8 assay. The results showed knockdown of PRKD2 increased the sensitivity of AML cells to ADM. (D) Cells were treated with 0.4 μg/mL (KASUMI) and 0.3 μg/mL (U937) ADM, and flow cytometry showed knockdown of PRKD2 increased ADM induced apoptosis of AML cells. *P < 0.05, **P < 0.01, ***P < 0.001.

HHS Vulnerability Disclosure